Linked Life Data

10202134

Source:http://linkedlifedata.com/resource/pubmed/id/10202134

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
2
pubmed:dateCreated
1999-7-7
pubmed:abstractText
The HER-2/neu oncogene encodes a transmembrane tyrosine kinase receptor with extensive homology to the epidermal growth factor receptor. HER-2/neu has been widely studied in breast cancer. The potential value of HER-2/neu status for the prediction of disease outcome and response to therapy in breast cancer is presented in the light of a series of recently published studies showing a range of impact on the outcome of patients treated with hormonal, cytotoxic and radiation therapies. This review includes the application of serum-based HER-2/neu testing and the use of antibody-based therapies directed against the HER-2/neu protein and their potential to become a new modality for breast cancer treatment.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Apr
pubmed:issn
1044-579X
pubmed:author
pubmed:copyrightInfo
Copyright 1999 Academic Press.
pubmed:issnType
Print
pubmed:volume
9
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
125-38
pubmed:dateRevised
2009-11-19
pubmed:meshHeading
pubmed:year
1999
pubmed:articleTitle
The HER-2/neu oncogene: prognostic factor, predictive factor and target for therapy.
pubmed:affiliation
Department of Pathology and Laboratory Medicine, Albany Medical College, 47 New Scotland Avenue, Albany, MA, NY 12208, USA.
pubmed:publicationType
Journal Article, Review